Life science news and medical media coverage for healthcare professionals
Healthcare Sys & Biz7 Sept 2026
Your white coat isn't the authority it once was. What is?Read article
Breast cancer home injections: Convenient for patients, complex for insurers
Despite the clinical benefits of home-based breast cancer therapy, insurance policies frequently impede patient access to these convenient injection programs.
Why are we still treating cancer prevention as adjunctive care?
Adopting a healthy lifestyle correlates with reduced risk for 13 distinct cancer types, highlighting the role of modifiable factors in oncology.
Brain metastases: Why less radiation, more often, improves outcomes
Multi-fraction stereotactic radiotherapy reduces local failure and radiation necrosis in resectable brain metastases compared to single-fraction approaches.
Multicancer tests: Can we screen without knowing the outcome?
Olaparib: Why HRD in breast and ovarian cancer goes beyond BRCA
Lung cancer in never smokers: The 60x risk factor you might be missing
Multicancer early detection: Can we screen for what we can't treat?
Salivary gland cancer: Is HER2-low the new HER2-positive?
Chemo hair loss: Why some patients feel it more deeply
ACLF: Why G-CSF works for some, but fails others
Specific immune cell populations and inflammatory markers predict G-CSF treatment response and mortality in acute-on-chronic liver failure, a GRAFT sub-study shows.
Pruritus in primary biliary cholangitis: the symptom that drives quality of life
Pruritus significantly impacts quality of life in primary biliary cholangitis, driving patient-reported outcomes and necessitating targeted management strategies.
MASH: Why diabetes management now demands a liver-first approach?
Emerging liver-directed approaches for moderate to advanced MASH are reshaping treatment paradigms, with significant implications for diabetes specialists managing metabolic dysfunction.
Seladelpar and elafibranor: second-line options for PBC
Chronic hepatitis B: Is PD-1 blockade the key to T-cell revival?
Liver disease: Is coffee a daily dose of prevention?
Why primary sclerosing cholangitis remains a therapeutic graveyard
Seladelpar and Elafibranor: The Second-Line Options for PBC After Ursodeoxycholic Acid Fails
Cholangiocarcinoma Surveillance: What Interval, What Modality in PSC?
Tactical athletes need more than a sports physical
New recommendations address cardiovascular screening and management for tactical athletes, focusing on unique physiological demands and risk factors in this population.
Peripheral arterial disease: Why early detection still eludes us
Peripheral arterial disease often goes undiagnosed until advanced stages, leading to preventable complications. Early detection is critical for improving patient outcomes.
LAA occlusion: Less bleeding, but is stroke risk truly equal?
Left atrial appendage occlusion (LAAO) reduces nonprocedural bleeding in AF patients but shows no difference in stroke or mortality compared to medical therapy.
Hypertension: Do shorter wall squats work as well for older women?
Beyond diagnosis: ECG waveforms predict MI-E treatment response
Evolocumab: Is LDL-C reduction finally translating to lives saved?
Endocarditis: Why fixed-dose ampicillin often misses the mark
GLP-1s: Is eligibility missing half your high-risk patients?
Rethinking xylitol: Is this 'healthy' sugar substitute a cardiac threat?
Survodutide: Is 9.8% weight loss enough for its GI cost?
SYNCHRONIZE-2 in NEJM: survodutide 6.0 mg cut weight 9.8% versus 3.9% on placebo over 76 weeks in type 2 diabetes, but about 1 in 4 stopped treatment.
Amylin plus tirzepatide: Is 23% weight loss the new benchmark?
Eloralintide combined with tirzepatide cut body weight by up to 23.3% at 48 weeks in adults with obesity and type 2 diabetes, phase 2b data show.
Type 1 diabetes screening: Why one protocol worked across 8 nations
EDENT1FI tested 140,568 young people and found early-stage type 1 diabetes in about 1 in 45 with a relative and 1 in 350 without, across 8 countries.
Bariatric surgery: The hidden hernia risk you're missing
Low-carb diets in kids with type 1 diabetes: safe, but not standard?
Marathon running with type 1 diabetes: Is it finally safe?
The 2026 ADA/EASD consensus: Why early SGLT2/GLP-1 works
Rotavirus vaccine and T1D: Is an 11% rise cause for alarm?
CBL-514: Is visceral fat reduction the real story?
Epilepsy: Is art the missing piece in holistic patient care?
A new exhibit showcases artists living with epilepsy, aiming to reframe public perception of the condition beyond its clinical manifestations.
Routine childhood vaccines: Less coverage means more than just infections
Routine childhood vaccination coverage has stagnated globally, with persistent inequities amplified by the COVID-19 pandemic, raising concerns for future health outcomes.
Can mice learn to control their own brains? A new neurofeedback system
A real-time closed-loop neurofeedback system allowed mice to modulate cortical activity and movement, adapting to rule changes for reward acquisition.
Fibromyalgia: Is the pain real if the tissue damage isn't?
Spike sorting: Is your 'black box' holding back neural insights?
Parkinson's cognitive decline: Is Juvmo the answer we overlooked?
Tau: Why its 'knockout' effect is a clue to Alzheimer's
Lifelong odor sensitivity: What early exposure means for your patients?
Brexpiprazole for Alzheimer's agitation: Antidepressants don't change efficacy
R-CHOP has been standard of care for 20 years. frontMIND may be the beginning of the end
An epidemiological shift in T2D is reshaping drug development and market access for oncology and metabolic portfolios.
The most resistant cancer is finally responding, and the pipeline is accelerating
Lecanemab and donanemab are approved. The harder question is who gets them and how
Label expansion triples the eligible population and the infrastructure race begins
LeukemiaRusfertide and hepcidin mimetics: a different way to control erythrocytosis
Get the full storyHaematocrit targets: Is 45% still the right threshold for phlebotomy?
Get the full storyWhy molecular response in polycythemia vera remains an elusive endpoint
Get the full storyPNH: Beyond Eculizumab, How Proximal Inhibition Reshaped Treatment Goals
Get the full storyWhen complement inhibitors fail: Recognizing breakthrough haemolysis
Get the full storyOral factor B inhibition: a new path for PNH management?
Get the full storyMyelofibrosis: Why transplant timing dictates survival, not just symptoms
Get the full storyChoosing a JAK Inhibitor in Myelofibrosis: Beyond Ruxolitinib
Get the full storyMomelotinib and anaemia in myelofibrosis: a new calculus for treatment?
Get the full storyGene therapy for thalassemia: Approval is one hurdle, access is the next
Get the full story
Idiopathic Pulmonary Fibrosis
Clostridioides difficile
Advertisement
• Oct 21 – 23ESMO 2026 • Madrid, ES 
• Oct 23 – 27ACR 2026 • Orlando, US 
• Nov 6 – 11AHA 2026 • Chicago, US • Nov 6 – 9ASH 2026 • New Orleans, US • Dec 12 – 15ACC.27 Together With WCC • Houston, US • Apr 10 – 12LIVEJoint ACTRIMS-ECTRIMS 2026 • Toronto, CA • Oct 21 – 23ESMO 2026 • Madrid, ES • Oct 23 – 27ACR 2026 • Orlando, US • Nov 6 – 11AHA 2026 • Chicago, US • Nov 6 – 9ASH 2026 • New Orleans, US • Dec 12 – 15ACC.27 Together With WCC • Houston, US • Apr 10 – 12AdvertisementAdvertisement
Advertisement
TorontoOct 21 – 23 2026Get on-site reporting the moment it publishes.
TorontoAttending Joint ACTRIMS-ECTRIMS 2026?
Get our free prep guide: key sessions by day, satellite symposia listings, and recommended spots near the venue.
Free. No spam. Unsubscribe anytime.
